FibroBiologics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving FibroBiologics, Inc. now
Current reporting with the operating signal separated from the noise.
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
The story matters when it changes FibroBiologics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.FibroBiologics, Inc. (NASDAQ:FBLG) CSO Invests ~$0.5M in Private Placement With Warrants
The story matters when it changes FibroBiologics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.FibroBiologics, Inc.: FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
The story matters when it changes FibroBiologics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.FibroBiologics, Inc.: FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement
Investors are testing whether FibroBiologics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
The story matters when it changes FibroBiologics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
The story matters when it changes FibroBiologics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.FibroBiologics, Inc. to Host Analyst Day on Fibroblast-Based Therapeutics in New York on February 12, 2025
The story matters when it changes FibroBiologics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest FBLG filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
FibroBiologics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →